Business Wire

Dr. Reddy's Laboratories Announces the Launch of Fulvestrant Injection, 250 mg/5 mL (50 mg/mL) per Single-Dose Syringe in the U.S. Market

HYDERABAD, India & PRINCETON, N.J.--(BUSINESS WIRE)--Dr. Reddy’s Laboratories Ltd. (BSE: 500124, NSE: DRREDDY, NYSE: RDY, along with its subsidiaries together referred to as “Dr. Reddy’s”) today ...
Monthly Prescribing Reference

FDA approves new dosing for Faslodex for breast cancer

AstraZeneca announced that the FDA has approved the 500mg dose of Faslodex (fulvestrant) injection, replacing the previously approved monthly dose of 250mg, for the treatment of hormone ...
Nasdaq

Mylan Expands Oncology Portfolio with Launch of Generic Faslodex® Injection, a Treatment for Advanced Breast Cancer

HERTFORDSHIRE, England and PITTSBURGH, Sept. 17, 2019 /PRNewswire/ -- Mylan N.V. (NASDAQ: MYL) today announced the U.S. launch of Fulvestrant Injection, 250 mg/5 mL (50 mg/mL) per single-dose ...
FiercePharma

FDA Approves New Dosing for FASLODEX® (fulvestrant) Injection in Treatment of Metastatic Breast Cancer in HR+ Postmenopausal Wom

(Logo: http://www.newscom.com/cgi-bin/prnh/20091027/PH99766LOGO) "This approval is an important advancement for women with metastatic breast cancer, where the ...
Cure Today

FDA Approves Ibrance Plus Faslodex for Hormone Receptor-Positive Breast Cancer

The U.S. Food and Drug Administration has approved Ibrance for use in combination with Faslodex in pretreated patients with hormone receptor-positive, HER2-negative metastatic breast cancer. The U.S.
Cure Today

Truqap/Faslodex Delays Time to Breast Cancer Progression, Next Therapy

Adding Truqap to Faslodex improved outcomes in patients with locally advanced or metastatic HR-positive, HER2-negative breast cancer. Patients with HR-positive, HER2-negative locally advanced or ...